Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | F13A1 | P00488 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130941 | 0.91 | PDPK1 (0.61) | PDPK1NPC1FFAR1FFAR4 | |
| SCHEMBL30437759 | 0.91 | PDPK1 (0.61) | PDPK1NPC1FFAR1FFAR4 | |
| SCHEMBL19584858 | 0.88 | NPC1 (0.45) | PDPK1NPC1FFAR1FFAR4F13A1 | |
| SCHEMBL15270886 | 0.84 | POLB (0.49) | PDPK1NPC1F13A1KDM4ETDP1 | |
| SCHEMBL6956901 | 0.82 | FFAR1 (0.50) | FFAR1FFAR4F13A1 | |
| SCHEMBL28629668 | 0.81 | F13A1 (0.46) | FFAR4F13A1KDM4ETDP1 | |
| SCHEMBL8828 | 0.80 | CA2 (0.54) | PDPK1NPC1MTNR1BAKR1B1AKR1A1 | |
| SCHEMBL29574729 | 0.80 | AKR1B1 (0.52) | PDPK1AKR1B1AKR1A1DGAT1 | |
| SCHEMBL5835 | 0.80 | AKR1B1 (0.52) | PDPK1AKR1B1AKR1A1DGAT1 | |
| SCHEMBL3883372 | 0.79 | PDPK1 (0.56) | PDPK1NPC1FFAR1FFAR4MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2213668-A2 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| CN-101605777-A | Imidazoles as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2009-12-16 | — | — | CN | disclosed |
| EP-2094680-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101300244-A | Novel cercosporamide derivative | DAIICHI SANKYO CO LTD (JP) | 2008-11-05 | — | — | CN | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | PDPK1 3597/4885NPC1 618/4885FFAR1 465/4885 |
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | PDPK1 1142/4885NPC1 1075/4885FFAR1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.